TAMSULOSINE ZENTIVA LAB LP 0.4 mg, extended-release capsule 30 capsules
Active ingredients: Tamsulosin hydrochloride, Tamsulosin
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule30 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TAMSULOSINE ZENTIVA LAB LP 0,4 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC PVDC aluminium de 30 gélule(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Mar 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66281345CIP73011196CIP133400930111963Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TAMSULOSINEgélule | 0,367 mg · une gélule | FT |
| CHLORHYDRATE DE TAMSULOSINEgélule | 0,4 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.